期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲状腺乳头状癌中PPM1D的表达和意义 被引量：2

Expression of PPM1D in papillary carcinoma of thyroid and its significance
下载PDF
导出
摘要 目的探讨甲状腺乳头状癌(papillary carcinoma of thyroid,PTC)中PPM1D蛋白的表达情况及其与临床病理特征和p53的关系。方法应用免疫组化EnVision法检测55例PTC及癌旁正常组织中PPM1D蛋白的表达情况并进行统计处理,分析其与临床病理特征的关系及和p53蛋白表达的相关性。结果 55例PTC中PPM1D的表达(74.5%,41/55)高于癌旁正常组织(10.9%,6/55),差异有统计学意义;PPPM1D的表达与患者年龄、性别、肿瘤大小、组织学类型、淋巴结转移、TNM分期无关,而在间质硬化的病例中表达增强(P<0.05);PTC中PPM1D与p53蛋白表达呈负相关(r=-0.339,P<0.05)。结论高表达的PPM1D与PTC相关,与p53之间可能存在相互作用,在PTC发生、发展中具有重要意义。 Purpose To investigate the expression of PPM1D in papillary carcinoma of thyroid （PTC） and its relationship with clinico- pathologic features and p53. Methods The expression of PPM1 D protein was detected in 55 cases of PTC tissues compared with nor- mal tumor-adjacent thyroid tissues by immunohistochemistry. The data was analyzed statistically to evaluate the relationship between the expression of PPM1 D, p53 and the clinicopathologic features. Results The expression of PPM1D was much higher in PTC （74. 5% , 41/55） than that in normal tumor-adjacent thyroid tissues（ 10. 9%, 6/55 ）. The difference was statistically significant（ P 〈 0. 05 ）. PPM1D was found high-expressed in PTC with interstitial cirrhosis （P 〈 0. 05 ）. PPM1D also showed negative correlation with p53 （r = - 0. 339, P 〈 0. 05 ） in PTC. Conclusions Increased expression of PPM1D is associated with thyroid papillary carcinoma and the po- tential coordination between PPM1D and p53 may play an important role in the process of tumor genesis and development.
作者 任伟民 张友元 罗金芳 叶宣光 董军明
机构地区 复旦大学附属金山医院病理科
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2012年第6期623-626,共4页 Chinese Journal of Clinical and Experimental Pathology
基金 上海市卫生局面上项目(2010-51)
关键词 甲状腺肿瘤 乳头状癌 PPM1D P53 免疫组织化学 thyroid neoplasms papillary carcinoma PPM1 D immunohistochemistry
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Fiscella M, Zhang H, Fan S, et al. Wipl, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner [ J ]. Proc Natl Acad Sci USA, 1997,94 (12) :6048 -53.
  • 2Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation : validation for oestrogen re- ceptor in breast carcinomas [ J ]. J Clin Pathol, 1995,48 (9) :876 - 8.
  • 3Le Guezennec X, Bulavin D V. WIP1 phosphatase at the cross- roads of cancer and aging [J]. Trends Biochem Sci,2010,35 ( 2 ) : 109 - 14.
  • 4Yu E,Ahn Y S,Jang S J,et al. Overexpression of the wipl gene abrogates the p38 MAPK/p53/Wipl pathway and silences p16 ex- pression in human breast cancers [ J ]. Breast Cancer Res Treat, 2007,101(3) :269 -78.
  • 5Shreeram S, Demidov 0 N, Hee W K,et al. Wipl phosphatase modulates ATM-dependent signaling pathways [ J ]. Mol Cell, 2006,23 (5) :757 - 64.
  • 6Yamaguchi H, Durell S R, Chatterjee D K,et al. The Wipl phos-phatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3 K-like kinases [ J ]. Biochemistry, 2007,46(44) :12594 -603.
  • 7Chew J,Biswas S,Shreeram S,et al. WIP1 phosphatase is a nega- tive regulator of NF-kappaB signaling[ J]. Nat Cell Bio1,2009,11 (5) :659 -66.
  • 8Bang J, Yamaguchi H, Durell S R, et al. A small molecular scaf- fold for selective inhibition of Wipl phosphatase[ J]. Chem Med Chem.2008.3 (2) :230 - 2.
  • 9Morita N,Ikeda Y,Takami H. Clinical significance of p53 protein expression in papillary thyroid carcinoma [ J ]. World J Surg, 2008,32(12) :2617 -22.
  • 10魏启幼,范松青,张利群.甲状腺乳头状腺癌中EGFR、nm23-H_1和p53蛋白的表达[J].临床与实验病理学杂志,1999,15(4):303-305. 被引量：6

二级参考文献31

  • 1栾复新,王孟薇,尤纬缔,祝庆孚.转化生长因子-α、表皮生长因子受体与胃癌发生的关系及其与增殖细胞核抗原的相关性分析[J].中华病理学杂志,1997,26(1):32-35. 被引量：26
  • 2Alessandrini A,Chiaur DS,Pagano M. Regulation of the cyclin-dependent kinase inhibitor P27 by degradation phosphorylation[J ]. Leukemia, 1997,11 (3) : 342-345.
  • 3Vlach J, Hennrecke S, Amati B. Phosphorylation-dependent kinase degradation of the cyclin-dependent kinase inhibitor p27kipl[J]. EMBO J,1997,16(17):5334-5344.
  • 4Sherr GJ. Cancer cell cycles [J ]. Science, 1996, 274 ( 5293 ) :1672-1677.
  • 5Tan P,Cady B,Wanner M,et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (Tla,b) invasive breast carcinoma[J]. Cancer Res, 1997,57(7) : 1259-1263.
  • 6Esposito V,Baldi A,De Luea A,et al. Prognostic role of the cell eyelin dependent kinase inhibitor p27 in non-small celllung carcinomas [J]. Cancer Res, 1997,57 ( 16 ).- 3381-3385.
  • 7Loda M, Cukor B, Tam SW,et al. Increased proteasome-dependent degradation o[ cyclin-dependant kinase inhibitor p27 in agressive colorectal carcinomas[J]. Nat Med, 1997,3(2) :231-234.
  • 8Yasui W, Kudo Y, Semba S,et al. Reduced expression of cyclin-dependent kinase inhibitor p27^kipl is associated with advanced stage and invasiveness of gastric carcinomas[J]. Jpn J Cancer Res,1997,88(7) :625-629.
  • 9Singh SP,Lipman J,Goldman H,et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma[J]. Cancer Res,1998,58(8) : 1730-1735.
  • 10Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-- free survival in patients with prostate cancer [J]. J Urol,1998,159(3):941-945.

共引文献17

同被引文献33

  • 1Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the fu ture of TNM[J]. Ann Surg Oncol,2010,17(6) :1471 -1474.
  • 2Liu J, Brown RE. Immunohistochemical detection of epithelial- mesenchymal transition associated with sternness phenotype in anaplastic thyroid carcinoma[J]. Int J Clin Exp Pathol, 2010,3(8) :755-762.
  • 3Rodriguez-Antona C, Pallares J, Montero-Conde C, et al. Overexpression and activation of EGFR and VEGFR2 in me dullary thyroid carcinomas is related to metastasi[J]. Endocr Relat Cancer, 2010,17 (1) : 7-16.
  • 4DeLellis RA, Lloyd RV, Heitz PU, et al. World health organi zation classification of turnouts, pathology and genetics of tumours of endocrine organs[M]. Lyon: IARC Press,2004: 57-66.
  • 5Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating me- senchymal cells[J]. J Cell Biol, 1982,95(1):333 -339.
  • 6Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-D-induced epithelial-mesenchymal transition facilitates epidermal growth factor dependent breast cancer progression [J]. Oncogene, 2010,29(49) :6485-6498.
  • 7Hu YY,Zheng MH, Zhang R, et al. Notch signaling pathway and cancer metastasis[J]. Adv Exp Med Biol, 2012,727 : 186- 198.
  • 8Cheng JC, Auersperg N, Leung PC. EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possi- ble step in the transition to low-grade serous carcinoma cells? [J]. PLoS One,2012,7(3) :e34071.
  • 9Lue HW, Yang X, Wang R, et al. LIV-1 promotes prostate cancer epithelial to mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signa ling[J].PLoS One,2011,6(11) :e27720.
  • 10Hunter T, Ling N,Cooper JA. Protein kinase C phosphoryla- tion of the EGF receptor at a threonine residue close to the cy toplasmic face of the plasma membran[J].Nature, 1984,311 (5985) :480-483.

引证文献2

二级引证文献7

临床与实验病理学杂志
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部